Utama › Kanser Paru-paru Bukan Sel Kecil › California › Roseville
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Roseville, CA
10 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Roseville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Kaiser Permanente-Roseville, Roseville
- Sutter Roseville Medical Center, Roseville
- Sutter Auburn Faith Hospital, Auburn · 15 mi jauh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Kaiser Permanente-Roseville, Roseville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Roseville Medical Plaza Care Center, Roseville
- Sutter Medical Center, Sacramento Infusion Center at Roseville, Roseville
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Mengambil pesertaFasa 3
- Sutter Health, Roseville
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Sutter Institute for Medical Research, Roseville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Kaiser Permanente-Roseville, Roseville
- Sutter Roseville Medical Center, Roseville
- Sutter Auburn Faith Hospital, Auburn · 15 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Sutter Roseville Medical Center, Roseville
- Sutter Auburn Faith Hospital, Auburn · 15 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Kaiser Permanente-Roseville, Roseville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Sutter Roseville Medical Center, Roseville
- Sutter Auburn Faith Hospital, Auburn · 15 mi jauh
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Kaiser Permanente-Roseville, Roseville
- Mercy Cancer Center - Rocklin, Rocklin · 4 mi jauh
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Roseville
- Kanser Paru-paru9 kajian
- Kanser Prostat8 kajian
- Kanser Payudara7 kajian
- Kanser Kolorektal6 kajian
- Diabetes Jenis 25 kajian
- Leukemia Mieloid Akut5 kajian
- Kanser Kolon5 kajian
- Kanser (semua jenis)4 kajian
- Kanser Ginjal (Karsinoma Sel Renal)4 kajian
- Mieloma Pelbagai3 kajian
- Kanser Ovari3 kajian
- Kanser Rektum3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.